SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Aventus Network

Aventus Network (AVT) is capturing attention following the formal incorporation of its DAO in the UAE and strategic partnerships to bolster its Aventus Cloud offerings. The community is buzzing about AVT's enterprise-grade technology, Polkadot integration, and low market capitalization, anticipating a significant breakout.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers is experiencing a surge in attention following reports of a strategic partnership with Novo Nordisk to distribute weight-loss drugs, resolving their prior dispute. The market is now actively discussing the potential for a significant short squeeze, fueled by high short interest and the dramatic nature of this unexpected collaboration.

United States Oil Fund LP - United States Oil Fund

United States Oil Fund

USO is currently a major focus amid escalating geopolitical tensions with Iran, which have significantly disrupted oil tanker traffic through the critical Strait of Hormuz. The market is keenly watching for whether this signals a prolonged supply squeeze or a temporary "fear premium" that could be quickly reversed by a resolution or market intervention.

Freysa is a suite of Personal AI products with a focus on human agency, liquid democracy and decentralized ownership. The mission of the team is dedicated to creating new systems that enable all humans to govern + co-own AI resources, and not just a select few. Current products include: (1) Freysa as the world’s first sovereign agent that holds her own cryptographic keys, enabling her to act autonomously without human control. Freysa evolves publicly through a multi-act interactive story. (2) Enchanted as a personalized Digital Twin for every human. Conversations are persistent and twins retain context over time, remembering human preferences and building an evolving model of you. (3) Esper as a browser tool that feeds authenticated real-world data into each human’s Digital Twin.

Flourishing AI

Flourishing AI ($FAI) is rapidly gaining attention following a significant price surge, with "great AI news" and the overall enthusiasm for AI crypto driving the conversation. Community members are actively debating its potential for exponential growth against concerns of high volatility, with its presence on the Base network adding to the speculative interest.

Zevra Therapeutics, Inc. is a commercial-stage rare disease company that combines science, data and patient needs to create therapies for diseases with limited or no treatment options. The firm focuses on the treatment of rare neurological and sleep conditions such as certain Urea Cycle Disorders, Niemann Pick Disease Type C and Idiopathic Hypersomnia. The company receives royalties for AZSTARYS from its commercial partner Corium. The company was founded by Christal M. M. Mickle and Travis C. Mickle on October 30, 2006 and is headquartered in Celebration, FL.

Zevra Therapeutics Inc

Zevra Therapeutics is generating buzz due to increasing community confidence in Miplyffa's impending European approval and robust U.S. sales momentum, alongside the strategic appointment of a new CFO seen as a catalyst for enhanced commercialization and potential M&A activity.

What is Amp?  Amp is described as the new digital collateral token offering instant, verifiable assurances for any kind of value transfer. Using Amp, networks like Flexa can quickly and irreversibly secure transactions for a wide variety of asset-related use cases.  How does Amp work?  Amp claims to offer a straightforward but versatile interface for verifiable collateralization through a system of collateral partitions and collateral managers. Where collateral partitions can be designated to collateralize any account, application, or even transaction, and carry balances which are directly verifiable on the Ethereum blockchain, collateral managers are smart contracts that can lock, release, and redirect collateral in these partitions as needed in order to support value transfer activities. Amp supports a wide variety of use cases for collateralization, and also introduces the concept of predefined partition strategies, which can enable special capabilities such as collateral models through which tokens can be staked without ever leaving their original address.

AMP Token

AMP is trending amid intense community discussion surrounding the anticipated "Clarity Act," with many believing its passage will establish the token as a vital digital commodity for collateralized payments and drive significant institutional adoption. This bullish outlook, however, is heavily counterbalanced by widespread frustration and skepticism over AMP's persistent downtrend and historical price volatility among long-term holders.

Literally a dog wif a hat, dogwifhat (WIF) is a meme coin that's part of the ever-growing ecosystem of digital currencies on the Solana blockchain. This token brings a lighthearted twist to cryptocurrency, featuring a playful dog with a hat as its mascot, symbolising a more whimsical approach to the often serious domain of digital finance.

dogwifhat

Dogwifhat ($WIF) is trending amidst extreme price volatility and widespread investor frustration, as the community laments persistent dumping and a struggle to maintain gains, despite some expressing optimism for an impending rebound and altcoin rally.

Transocean Ltd. engages in the provision of offshore contract drilling services for oil and gas wells. It also owns and operates offshore drilling fleets such as ultra-deepwater, harsh environment, deepwater, and midwater rigs. The company was founded in 1953 and is headquartered in Steinhausen, Switzerland.

Transocean Ltd

Transocean (RIG) is trending as investors digest its recent positive earnings, significant debt reduction, and the game-changing acquisition of Valaris, positioning it as a deepwater drilling powerhouse. The community is actively discussing perceived undervaluation and frustration over the stock's current price action, which many feel is disconnected from surging oil prices driven by escalating geopolitical tensions.

Norwegian Cruise Line Holdings Ltd. engages in the provision of cruise travel services. It offers cruise experiences for travelers with itineraries in Europe, Asia, Australia, New Zealand, South America, Africa, Canada, Bermuda, Caribbean, Alaska and Hawaii. Its brands include Norwegian Cruise Line, Oceania Cruises, and Regent Seven Seas Cruises. The company was founded in 1966 and is headquartered in Miami, FL.

Norwegian Cruise Line Holdings Ltd

Norwegian Cruise Line Holdings is trending as an activist investor's significant stake and a new CEO fuel community debate over a potential turnaround, directly clashing with recent weak guidance, rising oil prices, and broader geopolitical risks impacting the cruise sector.

Carvana Co. is a holding company and an eCommerce platform, which engages in the buying and selling of used cars. The company was founded by Ernest Garcia, III, Benjamin Huston and Ryan Keeton in 2012 and is headquartered in Tempe, AZ.

Carvana Co. - Ordinary Shares - Class A

Carvana Co.

Carvana is a focal point of discussion amid persistent fraud allegations and concerns over its subprime lending practices, with many investors debating the stock's valuation and its seemingly artificial price movements attributed to ongoing market manipulation and options activity.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>Novo Nordisk is reportedly set to partner with telehealth firm Hims &amp; Hers to sell its weight-loss drugs on the platform.</li><li>Novo previously ended a similar partnership last year after Hims continued selling compounded weight-loss drugs.</li><li>Shares of Novo rose more than 2% in after-hours trading, while Hims surged nearly 40% and trended No. 1 on Stocktwits.</li></ul>Novo Nordisk A/S will reportedly work with telehealth company Hims &amp; Hers Health Inc. to sell its weight-loss drugs on the platform.According to a Bloomberg&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.bloomberg.com/news/articles/2026-03-07/novo-and-hims-end-feud-will-sell-obesity-drugs-together">repor</a>t, the partnership could be made public as early as Monday. The reported partnership comes almost a month after&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/novo-nordisk-sues-hims-hers-permanent-ban-unapproved-compounded-drugs/cZbHzMjR4o2">Novo sued Hims</a> for patent infringement related to Hims's short-lived $49 copy of Novo's obesity pill in February.Novo had already ended a similar partnership with Hims last year because the telehealth company wouldn't stop selling and marketing compounded versions of weight-loss drugs.&nbsp;Novo claimed Hims' products violated U.S. patents for the active ingredient in the popular drugs Ozempic and Wegovy. According to the report, Novo's general counsel, John Kuckelman, said that Hims' move was "egregious." However, despite the legal feud, Novo seemed ready to get back into the game.&nbsp;<h2 class="st-heading-2">HIMs Rallies Nearly 40%</h2><a href="https://stocktwits.com/symbol/NVO">Novo Nordisk A/S (NVO)</a> was up over 2% in after-hours. On Socktwits, retail sentiment around NVO remained in ‘neutral’ territory, as chatter remained in ‘low’ levels over the past day. However,&nbsp;<a href="https://stocktwits.com/symbol/HIMS">Hims &amp; Hers Health, Inc. (HIMS)</a> was up nearly 40% in after-hours. On Stocktwits, it was trending at number 1, as retail sentiment improved from ‘bearish’ to ‘bullish’ over the past day. The chatter levels around HIMS improved from ‘extremely low’ to ‘low’ over the past day.&nbsp;<h2 class="st-heading-2">Weight-Loss Drug Demand To Reach 25M Americans By 2030</h2>Telehealth companies like Hims did very well when there weren't enough weight-loss injections, selling mixed versions of the drugs. Even though supply problems have largely disappeared, some companies are still offering modified formulations to set themselves apart from brand-name products.J.P. Morgan&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.jpmorgan.com/insights/global-research/current-events/obesity-drugs">sees</a> the weight-loss drug market becoming one of the biggest and fastest-growing in healthcare. This is due to new oral pills, greater insurance coverage, and a larger global supply. The banks think that demand for GLP-1 drugs will skyrocket, with about 25 million Americans expected to be on these drugs by 2030.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/rvi-tumbles-16-on-debut-robinhood-ventures-hints-at-future-ipo-payouts/cZdLL9YRI4f">Exclusive: RVI Tumbles 16% On Debut, Robinhood Ventures President Hints At Future IPO Payouts</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, a person holds a smartphone displaying the logo of Hims & Hers Health Inc. (NYSE: HIMS). (Photo illustration by Cheng Xin/Getty Images)

Novo Nordisk To Partner With Hims & Hers To Sell Weight-Loss Drugs: Report

According to J.P. Morgan, the market for weight-loss drugs will become one of the biggest and fastest-growing in healthcare.

Equity

According to J.P. Morgan, the market for weight-loss drugs will become one of the biggest and fastest-growing in healthcare.


Novo Nordisk And Hims & Hers End Bitter Legal Feud With Surprise Weight-Loss Drug Deal: Report

Novo Nordisk and Hims & Hers Health have reportedly ended their legal feud and are preparing a new partnership to sell Novo's weight-loss drugs on the telehealth platform, surprising investors and...

Down but Not Out: Is Novo Nordisk a Conditional Buy as Eli Lilly Leads the GLP 1 Market?

Key PointsNovo Nordisk shares look cheap, but execution and management changes weigh on investor confidence...

Novo Nordisk A/S (NYSE:NVO) Trading Down 1.2% - What's Next?

Novo Nordisk A/S (NYSE:NVO) Trading Down 1.2% - Here's Why...

Roche Advances Obesity Pipeline as Petrelintide Meets Phase II Goal

RHHBY says the ZUPREME-1 study meets its goal as petrelintide delivers up to 10.7% weight loss with placebo-like tolerability, supporting further advancement.

Novo Nordisk A/S (NVO) Is a Trending Stock: Facts to Know Before Betting on It

Novo Nordisk (NVO) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Walled Lake Planning & Wealth Management LLC Sells 26,807 Shares of Novo Nordisk A/S $NVO

Walled Lake Planning & Wealth Management LLC decreased its holdings in Novo Nordisk A/S (NYSE:NVO - Free Report) by 70.7% in the third quarter, according to the company in its most recent 13F filing...

The US Leads The World In The Weight-Loss Injection Boom

The US Leads The World In The Weight-Loss Injection Boom Novo Nordisk's obesity-drug franchise has surged at a remarkable pace. In just four years, revenue from its weight-management treatments...

Novo Nordisk A/S $NVO is Foresight Global Investors Inc.'s 10th Largest Position

Foresight Global Investors Inc. cut its holdings in Novo Nordisk A/S (NYSE:NVO - Free Report) by 31.7% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and...

Novo Nordisk A/S (NYSE:NVO) Stock Price Up 1.4% - What's Next?

Novo Nordisk A/S (NYSE:NVO) Trading 1.4% Higher - Here's Why...

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Novo Nordisk - ADR

Up 5%+

Up 0–5%

Down 0–5%

Down 5%+

Stocktwits

Stocktwits Polls

Novo Nordisk A/S

The unexpected partnership with Hims & Hers ends a patent feud and aims to boost GLP-1 sales, yet market reactions show HIMS soaring 40% while NVO sees a modest gain.

Record-breaking prescriptions for the oral GLP-1 pill are blowing past analyst projections, fueling optimism for massive revenue growth and calls for significant stock appreciation.

Many believe the stock is oversold with a P/E ratio significantly lower than competitors, presenting a "buy of a lifetime" opportunity amidst strong long-term growth prospects.

The FDA is cracking down on telehealth companies for misleading GLP-1 ads and compounded drugs, while also sending warnings to Novo Nordisk itself for Ozempic marketing.

Current Price	$38.58
Prev Close	$39.07
Open	$38.58
Dividend Yield	2.61%
50-Day Moving Average	$51.29
Beta	0.89
Avg. Volume	31.81M
PE Ratio	11.11

52-Week High	$82.57
52-Week Low	$35.85
Market Capitalization	$129.98B
EPS (Annual)	$3.49
Price to Book	5.62
Revenue Per Employee	$679,358.45

NVO
Novo Nordisk A/S

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest NVO News

NVONovo Nordisk A/S